Literature DB >> 19389479

Nitric oxide enhances osteoclastogenesis possibly by mediating cell fusion.

Dorrin Nilforoushan1, Azza Gramoun, Michael Glogauer, Morris F Manolson.   

Abstract

Osteoclasts are multinucleated bone resorbing cells which form by fusion of pre-osteoclasts. Here, we investigate how nitric oxide (NO) affects osteoclastogenesis. Time lapse photomicrography, using the fluorescent NO indicator dye, 4,5-diaminofluorescein diacetate, revealed an intense NO signal in pre-osteoclasts preceding cell fusion. Osteoclastogenesis in RAW264.7 cells increased when exposed to the NO synthase inhibitor, L-NMMA (0.25 microM), for the initial 48 h. In contrast, pre-osteoclast fusion decreased when RAW264.7 cells were exposed to L-NMMA from 48 to 96 h. Both NO synthase inhibitors, L-NMMA and L-NAME, decreased osteoclast formation during this time period. The inhibitory effect of L-NMMA on osteoclast formation was abolished with increasing concentrations (25-200 ng/ml) of sRANKL suggesting signaling cross talk. NO donors increased osteoclast formation in a dose-dependent manner, with greatest stimulation at 15 microM NOC-12 (2.3 fold) and 5 microM NOC-18 (2.4 fold). Measuring nitrite (NO end product) daily from culture media of RAW264.7 cells undergoing osteoclastogenesis revealed that an increase in NO production coincided with the fusion of pre-osteoclasts (day 4). Inhibiting fusion by plating cells on polystyrene dishes pre-coated with poly-(L-lysine) decreased both osteoclast formation and NO production. To address if NO mediates fusion through the actin cytoskeleton, actin free barbed ends were measured. 0.25 microM L-NMMA decreased, while 15 microM NOC-12 and 5 microM NOC-18 increased actin free barbed ends. We hypothesize that while NO initially negatively regulates pre-osteoclast differentiation; it later facilitates the fusion of mononuclear pre-osteoclasts, possibly by up regulating actin remodeling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389479     DOI: 10.1016/j.niox.2009.04.002

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  20 in total

Review 1.  Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues.

Authors:  Scott P Nichols; Wesley L Storm; Ahyeon Koh; Mark H Schoenfisch
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

2.  [Pathophysiology and etiology of the Charcot foot].

Authors:  K Trieb; S G Hofstätter
Journal:  Orthopade       Date:  2015-01       Impact factor: 1.087

Review 3.  Updates on Diabetic Foot and Charcot Osteopathic Arthropathy.

Authors:  Brian M Schmidt; Crystal M Holmes
Journal:  Curr Diab Rep       Date:  2018-08-15       Impact factor: 4.810

4.  Interaction of Brucella abortus with Osteoclasts: a Step toward Understanding Osteoarticular Brucellosis and Vaccine Safety.

Authors:  Omar H Khalaf; Sankar P Chaki; Daniel G Garcia-Gonzalez; Larry J Suva; Dana Gaddy; Angela M Arenas-Gamboa
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

Review 5.  Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases.

Authors:  Danielle A Callaway; Jean X Jiang
Journal:  J Bone Miner Metab       Date:  2015-03-26       Impact factor: 2.626

6.  Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

Authors:  Anandi Sawant; Jessy Deshane; Joel Jules; Carnella M Lee; Brittney A Harris; Xu Feng; Selvarangan Ponnazhagan
Journal:  Cancer Res       Date:  2012-12-14       Impact factor: 12.701

7.  TRAP-positive osteoclast precursors mediate ROS/NO-dependent bactericidal activity via TLR4.

Authors:  Kazuaki Nishimura; Satoru Shindo; Alexandru Movila; Rayyan Kayal; Albassam Abdullah; Irma Josefina Savitri; Atsushi Ikeda; Tsuguno Yamaguchi; Mohammed Howait; Ayman Al-Dharrab; Abdulghani Mira; Xiaozhe Han; Toshihisa Kawai
Journal:  Free Radic Biol Med       Date:  2016-06-22       Impact factor: 7.376

8.  Peroxiredoxin II negatively regulates lipopolysaccharide-induced osteoclast formation and bone loss via JNK and STAT3.

Authors:  Hyojung Park; A Long Sae Mi Noh; Ju-Hee Kang; Jung-Sun Sim; Dong-Seok Lee; Mijung Yim
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

9.  Evaluation of methylation status of the eNOS promoter at birth in relation to childhood bone mineral content.

Authors:  Nicholas C Harvey; Karen A Lillycrop; Emma Garratt; Allan Sheppard; Cameron McLean; Graham Burdge; Jo Slater-Jefferies; Joanne Rodford; Sarah Crozier; Hazel Inskip; Bright Starling Emerald; Catharine R Gale; Mark Hanson; Peter Gluckman; Keith Godfrey; Cyrus Cooper
Journal:  Calcif Tissue Int       Date:  2011-12-08       Impact factor: 4.333

10.  Plasma membrane calcium ATPase regulates bone mass by fine-tuning osteoclast differentiation and survival.

Authors:  Hyung Joon Kim; Vikram Prasad; Seok-Won Hyung; Zang Hee Lee; Sang-Won Lee; Aditi Bhargava; David Pearce; Youngkyun Lee; Hong-Hee Kim
Journal:  J Cell Biol       Date:  2012-12-24       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.